.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,020,320

« Back to Dashboard

Details for Patent: 6,020,320

Title: Acyl deoxyribonucleoside derivatives and uses thereof
Abstract:The invention relates to compositions comprising acyl derivatives of 2'-deoxyribonucleosides. The invention also relates to methods of treating or preventing radiation, mutagen and sunlight-induced cellular damage, methods for improving wound healing and tissue repair, and methods for ameliorating the effects of aging comprising administering the compositions of the present invention to an animal.
Inventor(s): von Borstel; Reid Warren (Kensington, MD), Bamat; Michael Kevin (Chevy Chase, MD)
Assignee: Pro-Neuron, Inc. (Gaithersburg, MD)
Filing Date:Nov 17, 1993
Application Number:08/153,163
Claims:1. A method for enhancing the healing of skin wounds comprising administering to an animal in need thereof a wound-healing effective amount of a composition comprising acylated 2'-deoxyguanosine (II) and acylated 2'-deoxycytidine (III) having the structure:

2'-deoxyguanosine (II) ##STR12## 2'-deoxycytidine (III) ##STR13## wherein R is H or an acyl group derived from a carboxylic acid selected from one or more of the group consisting of pyruvic acid, lactic acid, enolpyruvic acid, an amino acid, a fatty acid containing 2 or more carbon atoms, lipoic acid, nicotinic acid, pantothenic acid, succinic acid, fumaric acid, p-aminobenzoic acid, betahydroxybutyric acid, orotic acid and carnitine, with the proviso that at least one R substituent is not hydrogen, or the pharmaceutically acceptable salt thereof.

2. A method for enhancing the healing of burned tissue comprising administering to an animal in need thereof a burned tissue-healing effective amount of a composition comprising acylated 2'-deoxyguanosine (II) and acylated 2'-deoxycytidine (III) having the structure:

2'-deoxyguanosine (II) ##STR14## ' -deoxycytidine (III) ##STR15## wherein R is H or an acyl group derived from a carboxylic acid selected from one or more of the group consisting of pyruvic acid, lactic acid, enolpyruvic acid, an amino acid, a fatty acid containing 2 or more carbon atoms, lipoic acid, nicotinic acid, pantothenic acid, succinic acid, fumaric acid, p-aminobenzoic acid, betahydroxybutyric acid, orotic acid and carnitine, with the proviso that at least one R substituent is not hydrogen, or the pharmaceutically acceptable salt thereof.

3. A method for enhancing the healing of diseased or damaged liver tissue comprising administering to an animal in need thereof an effective amount of a composition comprising acylated 2'-deoxyguanosine (II) and acylated 2'-deoxycytidine (III) having the structure:

' -deoxyguanosine (II) ##STR16## 2'-deoxycytidine (III) ##STR17## wherein R is H or an acyl group derived from a carboxylic acid selected from one or more of the group consisting of pyruvic acid, lactic acid, enolpyruvic acid, an amino acid, a fatty acid containing 2 or more carbon atoms, lipoic acid, nicotinic acid, pantothenic acid, succinic acid, fumaric acid, p-aminobenzoic acid, betahydroxybutyric acid, orotic acid and carnitine, with the proviso that at least one R substituent is not hydrogen, or the pharmaceutically acceptable salt thereof.

4. A method for enhancing the healing of bone marrow comprising administering to an animal in need thereof an effective amount of a composition acylated 2'-deoxyguanosine (II) and acylated 2'-deoxycytidine (III) having the structure:

2'-deoxyguanosine (II) ##STR18## 2'-deoxycytidine (III) ##STR19## wherein R is H or an acyl group derived from a carboxylic acid selected from one or more of the group consisting of pyruvic acid, lactic acid, enolpyruvic acid, an amino acid, a fatty acid containing 2 or more carbon atoms, lipoic acid, nicotinic acid, pantothenic acid, succinic acid, fumaric acid, p-aminobenzoic acid, betahydroxybutyric acid, orotic acid and carnitine, with the proviso that at least one R substituent is not hydrogen, or the pharmaceutically acceptable salt thereof.

5. A method as in claim 1 wherein said composition further comprises one or more of the acylated 2'-deoxyribonucleosides selected from the group consisting of:

2'-deoxyadenosine (I), ##STR20## 2'-deoxythymidine (IV) ##STR21## ' -deoxythymidine (V) ##STR22## wherein in the case of compounds I and IV, R is H or an acyl group derived from a carboxylic acid selected from one or more of the group consisting of pyruvic acid, lactic acid, enolpyruvic acid, an amino acid, a fatty acid containing 2 or more carbon atoms, lipoic acid, nicotinic acid, pantothenic acid, succinic acid, fumaric acid, p-aminobenzoic acid, betahydroxybutyric acid, orotic acid and carnitine, with the proviso that at least one R substituent is not hydrogen, or the pharmaceutically acceptable salt thereof, and

in the case of compound (V), R" is H or an acyl group derived from a carboxylic acid selected from one or more of the group consisting of pyruvic acid, lactic acid, enolpyruvic acid, an amino acid, a fatty acid, lipoic acid, nicotinic acid, pantothenic acid, succinic acid, fumaric acid, p-aminobenzoic acid, betahydroxybutyric acid, orotic acid and carnitine, with the proviso that the R" on nitrogen is not hydrogen, or the pharmaceutically salt thereof.

6. A method as in claim 2 wherein said composition further comprises one or more of the acylated 2'-deoxyribonucleosides selected from the group consisting of:

2'-deoxyadenosine (I), ##STR23## 2'-deoxythymidine (IV) ##STR24## 2'-deoxythymidine (V) ##STR25## wherein in the case of compounds I and IV, R is H or an acyl group derived from a carboxylic acid selected from one or more of the group consisting of pyruvic acid, lactic acid, enolpyruvic acid, an amino acid, a fatty acid containing 2 or more carbon atoms, lipoic acid, nicotinic acid, pantothenic acid, succinic acid, fumaric acid, p-aminobenzoic acid, betahydroxybutyric acid, orotic acid and carnitine, with the proviso that at least one R substituent is not hydrogen, or the pharmaceutically acceptable salt thereof, and

in the case of compound (V), R" is H or an acyl group derived from a carboxylic acid selected from one or more of the group consisting of pyruvic acid, lactic acid, enolpyruvic acid, an amino acid, a fatty,acid, lipoic acid, nicotinic acid, pantothenic acid, succinic acid, fumaric acid, p-aminobenzoic acid, betahydroxybutyric acid, orotic acid and carnitine, with the proviso that the R" on nitrogen is not hydrogen, or the pharmaceutically salt thereof.

7. A method as in claim 3 wherein said composition further comprises one or more of the acylated 2'-deoxyribonucleosides selected from the group consisting of:

2'-deoxyadenosine (I), ##STR26## 2'-deoxythymidine (IV) ##STR27## ' -deoxythymidine (V) ##STR28## wherein in the case of compounds I and IV, R is H or an acyl group derived from a carboxylic acid selected from one or more of the group consisting of pyruvic acid, lactic acid, enolpyruvic acid, an amino acid, a fatty acid containing 2 or more carbon atoms, lipoic acid, nicotinic acid, pantothenic acid, succinic acid, fumaric acid, p-aminobenzoic acid, betahydroxybutyric acid, orotic acid and carnitine, with the proviso that at least one R substituent is not hydrogen, or the pharmaceutically acceptable salt thereof, and

in the case of compound (V), R" is H or an acyl group derived from a carboxylic acid selected from one or more of the group consisting of pyruvic acid, lactic acid, enolpyruvic acid, an amino acid, a fatty acid, lipoic acid, nicotinic acid, pantothenic acid, succinic acid, fumaric acid, p-aminobenzoic acid, betahydroxybutyric acid, orotic acid and carnitine, with the proviso that the R" on nitrogen is not hydrogen, or the pharmaceutically salt thereof.

8. A method as in claim 4 wherein said composition further comprises one or more of the acylated 2'-deoxyribonucleosides selected from the group consisting of:

2'-deoxyadenosine (I), ##STR29## 2'-deoxythymidine (IV) ##STR30## ' -deoxythymidine (V) ##STR31## wherein in the case of compounds I and IV, R is H or an acyl group derived from a carboxylic acid selected from one or more of the group consisting of pyruvic acid, lactic acid, enolpyruvic acid, an amino acid, a fatty acid containing 2 or more carbon atoms, lipoic acid, nicotinic acid, pantothenic acid, succinic acid, fumaric acid, p-aminobenzoic acid, betahydroxybutyric acid, orotic acid and carnitine, with the proviso that at least one R substituent is not hydrogen, or the pharmaceutically acceptable salt thereof, and

in the case of compound (V), R" is H or an acyl group derived from a carboxylic acid selected from one or more of the group consisting of pyruvic acid, lactic acid, enolpyruvic acid, an amino acid, a fatty acid, lipoic acid, nicotinic acid, pantothenic acid, succinic acid, fumaric acid, p-aminobenzoic acid, betahydroxybutyric acid, orotic acid and carnitine, with the proviso that the R" on nitrogen is not hydrogen, or the pharmaceutically salt thereof.

9. A method as in claim 1 wherein R is acetyl and R"" is acetyl, propionyl or butyryl, with the proviso that at least one R or R"" is not hydrogen, or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

10. A method as in claim 2 wherein R is acetyl and R"" is acetyl, propionyl or butyryl, with the proviso that at least one R or R"" is not hydrogen, or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

11. A method as in claim 3 wherein R is acetyl and R"" is acetyl, propionyl or butyryl, with the proviso that at least one R or R"" is not hydrogen, or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

12. A method as in claim 4 wherein R is acetyl and R"" is acetyl, propionyl or butyryl, with the proviso that at least one R or R"" is not hydrogen, or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc